Lentivector immunization induces tumor antigen‐specific B and T cell responses <i>in vivo</i>

Casado, Javier G.; Janda, Jozef; Wei, Joe; Chapatte, Laurence; Colombetti, Sara; Alves, Pedro M. Sousa; Ritter, Gerd; Ayyoub, Maha; Valmori, Danila; Chen, Weisan; Lévy, Frédéric

doi:10.1002/eji.200737923

Cited by 20 publications

(10 citation statements)

References 35 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, an LV encoding the human melanoma antigen, NY‐ESO‐1, stimulated a CD4 + T‐cell response against a newly identified NY‐ESO‐1 86–99 epitope that was presented by H2 I‐Ab (64). Furthermore, depletion of the CD4 + T cells resulted in the complete abrogation of B‐cell and CD8 + T‐cell responses against NY‐ESO‐1 (162). Thus, vaccines that are able to stimulate both CD4 + and CD8 + T‐cell responses will result in better overall immune responses.…”

Section: As a Tumor Vaccinementioning

confidence: 99%

Immunization delivered by lentiviral vectors for cancer and infectious diseases

Tai

Wang

2010

Immunological Reviews

View full text Add to dashboard Cite

SummaryThe increasing level of understanding of the lentivirus biology has been instrumental in shaping the design strategy of creating therapeutic lentiviral delivery vectors. As a result, lentiviral vectors have become one of the most powerful gene transfer vehicles. They are widely used for therapeutic purposes as well as in studies of basic biology, due to their unique characteristics. Lentiviral vectors have been successfully employed to mediate durable and efficient antigen expression and presentation in dendritic cells both in vitro and in vivo, leading to the activation of cellular immunity and humoral responses. This capability makes the lentiviral vector an ideal choice for immunizations that target a wide range of cancers and infectious diseases. Further advances into optimizing the vector system and understanding the relationship between the immune system and diseases pathogenesis will only augment the potential benefits and utility of lentiviral vaccines for human health.

show abstract

Section: As a Tumor Vaccinementioning

confidence: 99%

Immunization delivered by lentiviral vectors for cancer and infectious diseases

Tai

Wang

2010

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…The frequency of epitope-specific SFCs was 106 Ϯ 67/10 6 splenocytes for SL3261-ESO9 or 104 Ϯ 59/10 6 splenocytes for SL3261-ESO11. In a former study, a lentivirus-based NY-ESO-1 vaccine elicited a three times greater T-cell response, which may have been due to the high level of replication of lentivirus in the spleen, but this approach needed a subcutaneous injection and had a biosafety problem (9,23). Another study employed a Salmonella serovar Typhimurium vaccine strain to deliver NY-ESO-1 through a type III protein secretion system and showed a rate of IFN-␥-secreting T cells and tumor regression in mice similar to that found in the present study (25).…”

Section: Cd25mentioning

confidence: 99%

Oral Vaccination with AttenuatedSalmonella entericaStrains Encoding T-Cell Epitopes from Tumor Antigen NY-ESO-1 Induces Specific Cytotoxic T-Lymphocyte Responses

Meng

Dong

Huang

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Bacterial fimbriae can accept foreign peptides and display them on the cell surface. A highly efficient gene replacement method was used to generate peptide vaccines based on Salmonella enterica serovar Typhimurium SL3261. The T-cell epitopes (NY-ESO-1 p157-165 and p157-167) from NY-ESO-1, which is a promising target antigen in patients for the specific immune recognition of cancer, were incorporated into the gene encoding AgfA (the major subunit protein of thin aggregative fimbriae of Salmonella) by replacing an equal length of the DNA segment. To improve cytotoxic T-lymphocyte recognition, both termini of the peptide were flanked by double alanine (AA) residues. Immunofluorescence microscopy with AgfA-specific antiserum verified the expression of chimeric AgfA, which was also proved by a Congo red binding assay. Modulating the immune system to control cancer has been a challenge for cancer immunotherapists for many years. A number of clinical trials have indeed demonstrated that objective tumor regressions can occur in the setting of cancer vaccinations (1,19,31

show abstract

“…HIV-1 derived lentiviral vector (LV) are very potent at inducing strong and broad cellular and humoral memory responses [23], [24], [25], [26], [27]. They provide protective immunity against many tumors and infectious diseases as shown in mice and monkeys [28], [29], [30], [31].…”

Section: Introductionmentioning

confidence: 99%

A Nonintegrative Lentiviral Vector-Based Vaccine Provides Long-Term Sterile Protection against Malaria

et al. 2012

View full text Add to dashboard Cite

Trials testing the RTS,S candidate malaria vaccine and radiation-attenuated sporozoites (RAS) have shown that protective immunity against malaria can be induced and that an effective vaccine is not out of reach. However, longer-term protection and higher protection rates are required to eradicate malaria from the endemic regions. It implies that there is still a need to explore new vaccine strategies. Lentiviral vectors are very potent at inducing strong immunological memory. However their integrative status challenges their safety profile. Eliminating the integration step obviates the risk of insertional oncogenesis. Providing they confer sterile immunity, nonintegrative lentiviral vectors (NILV) hold promise as mass pediatric vaccine by meeting high safety standards. In this study, we have assessed the protective efficacy of NILV against malaria in a robust pre-clinical model. Mice were immunized with NILV encoding Plasmodium yoelii Circumsporozoite Protein (Py CSP) and challenged with sporozoites one month later. In two independent protective efficacy studies, 50% (37.5–62.5) of the animals were fully protected (p = 0.0072 and p = 0.0008 respectively when compared to naive mice). The remaining mice with detectable parasitized red blood cells exhibited a prolonged patency and reduced parasitemia. Moreover, protection was long-lasting with 42.8% sterile protection six months after the last immunization (p = 0.0042). Post-challenge CD8+ T cells to CSP, in contrast to anti-CSP antibodies, were associated with protection (r = −0.6615 and p = 0.0004 between the frequency of IFN-g secreting specific T cells in spleen and parasitemia). However, while NILV and RAS immunizations elicited comparable immunity to CSP, only RAS conferred 100% of sterile protection. Given that a better protection can be anticipated from a multi-antigen vaccine and an optimized vector design, NILV appear as a promising malaria vaccine.

show abstract

Lentivector immunization induces tumor antigen‐specific B and T cell responses in vivo

Cited by 20 publications

References 35 publications

Immunization delivered by lentiviral vectors for cancer and infectious diseases

Immunization delivered by lentiviral vectors for cancer and infectious diseases

Oral Vaccination with AttenuatedSalmonella entericaStrains Encoding T-Cell Epitopes from Tumor Antigen NY-ESO-1 Induces Specific Cytotoxic T-Lymphocyte Responses

A Nonintegrative Lentiviral Vector-Based Vaccine Provides Long-Term Sterile Protection against Malaria

Contact Info

Product

Resources

About